Observational studyJournal of thrombosis and haemostasis : JTH2021
Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001-2018.
Observational study in Journal of thrombosis and haemostasis : JTH, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07187661 (Efficacy of Intra-Articular Bevacizumab in Preventing Recurrent Hemarthrosis in Hemophilia Patients With Chronic Synovitis), which is not on this map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Intra-Articular Bevacizumab in Preventing Recurrent Hemarthrosis in Hemophilia Patients With Chronic Synovitis: A Pre- and Post-Design Study
Who cites it
48 citing papers in PubMed, 91 citations in OpenAlex.
- Life expectancy of people with hemophilia in France in 2022.European journal of epidemiology · 2026Article
- Minimally invasive coronary artery bypass grafting via a left lateral mini-thoracotomy in severe hemophilia A: a case report.General thoracic and cardiovascular surgery cases · 2026Article
- Review
- Planning Renal Replacement Therapy in Factor VII Deficiency.Kidney international reports · 2026Article
- Race, Ethnicity, and Hemophilia: A Scoping Review.Journal of racial and ethnic health disparities · 2026Review
- A Paradigm Shift in Hemophilia Care: The Promise of Gene Therapy.Current gene therapy · 2026Review
- Disease burden and unmet medical need in severe hemophilia in Greece: insights from clinicians and patients.Frontiers in public health · 2026Article
- The aging hemophilia patient.Hematology. American Society of Hematology. Education Program · 2025Review
- Trends in concomitant cerebrovascular disease and coagulation disorders-related mortality in the United States, 1999-2020.Thrombosis journal · 2025Article
- Spinal Stenosis: An Emerging Complication of Ageing in People With Haemophilia.Haemophilia : the official journal of the World Federation of Hemophilia · 2025Article
- A Hemophilia Joint Health Score-Based Model for the Economic Evaluation of Hemophilia A Prophylaxis Interventions.PharmacoEconomics · 2025Article
- Burden of Haemophilia A in South Korea: A Serial Cross-Sectional Study From 2008 to 2021.Haemophilia : the official journal of the World Federation of Hemophilia · 2025Article
- Mild or moderate hemophilia is not always a mild or moderate bleeding disorder: Back to the clinical phenotype.HemaSphere · 2025Article
- Quality-of-Life Assessment and Pharmacokinetic Study in Hemophilia A Patients Undergoing Prophylactic Treatment.Pharmacy (Basel, Switzerland) · 2025Article
- Nonsevere Hemophilia: The Need for a Renewed Focus and Improved Outcomes.Seminars in thrombosis and hemostasis · 2025Review
- Global patterns of hemophilia drug trials, hemophilia care, and health care measures.Research and practice in thrombosis and haemostasis · 2025Article
- Lifetime economic burden of hemophilia using a nationwide real-world healthcare data.PloS one · 2025Article
- What is a cure through gene therapy? An analysis and evaluation of the use of "cure".Medicine, health care, and philosophy · 2024Article
- Article
- Combination of bolus and continuous infusion of factor VIII in a patient with severe hemophilia A undergoing on-pump coronary artery bypass graft surgery.Clinical case reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTreatment of patients with hemophilia has advanced over the past decades, but it is unknown whether this has resulted in a normal life expectancy in the Netherlands.
objectiveThis observational cohort study aimed to assess all-cause and cause-specific mortality in patients with hemophilia in the Netherlands between 2001 and 2018 and to compare mortality and life expectancy with previous survival assessments from 1973 onward. PATIENTS/
methodsAll 1066 patients with hemophilia who participated in a nationwide survey in 2001 were followed until July 2018.
resultsInformation on 1031 individuals (97%) was available, of whom 142 (14%) deceased during follow-up. Compared with the general Dutch male population, mortality of patients with hemophilia was still increased (standardized mortality ratio: 1.4, 95% confidence interval: 1.2-1.7). Intracranial bleeding and malignancies were the most common causes of death. Estimated median life expectancy of patients with hemophilia was 77 years, 6 years lower than the median life expectancy of the general Dutch male population (83 years). Over the past 45 years, death rates of patients with hemophilia have consistently decreased, approaching the survival experience of the general population. Over the past decades, mortality due to human immunodeficiency virus and hepatitis C virus infections has decreased, death due to intracranial hemorrhages has increased, and death due to ischemic heart disease has remained consistently low over time.
conclusionsSurvival in patients with hemophilia in the Netherlands has improved over time but is still lower than that of the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.